Press release
Investigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA)
An investigation for investors in Innate Pharma S.A. (NASDAQ: IPHA) shares over potential securities laws violations.
Investors who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Innate Pharma S.A. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
France based Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. Innate Pharma S.A. reported that its annual Total Revenue rose from $32.63 million in 2017 to $79.89 million in 2018, and that its Net Loss of $48.01 million in 2017 turned to a Net Income of $3.04 million in 2018.
On January 9, 2020, Innate Pharma S.A. announced its decision “to suspend enrollment of new patients” in its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. Innate cited “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.”
Shares of Innate Pharma S.A. (NASDAQ: IPHA) declined from $8.24 per share on January 2, 2020 to as low as $6.70 per share on January 9, 2020
Those who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA) here
News-ID: 1897264 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainme …
An investigation on behalf of current long-term investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) concerning potential breaches of fiduciary duties by certain directors of WEBTOON Entertainment Inc. was announced.
Investors who are current long term investors in WEBTOON Entertainment Inc. (NASDAQ: WBTN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Deadline on Nov. 19th coming up in Lawsuit for Investors who lost money with Dom …
A deadline is coming up on November 19, 2024 in the lawsuit filed for certain investors of Domino's Pizza, Inc. (NYSE: DPZ) over alleged securities laws violations by Domino's Pizza, Inc.
Investors who purchased shares of Domino's Pizza, Inc. (NYSE: DPZ) have certain options and there are strict and short deadlines running. Deadline: November 19, 2024. NYSE: DPZ stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Lawsuit filed for Investors who lost money with shares of United Parcel Service, …
An investor, who purchased shares of United Parcel Service, Inc. (NYSE: UPS), filed a lawsuit over alleged violations of Federal Securities Laws by United Parcel Service, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of United Parcel Service, Inc. (NYSE: UPS) have certain options and for certain investors are short and strict deadlines running. Deadline: December 9, 2024. NYSE: UPS investors should contact the Shareholders…
Long-Term Investors in shares of Palo Alto Networks, Inc. (NASDAQ: PANW) should …
An investigation was announced for current long-term investors in shares of Palo Alto Networks, Inc. (NASDAQ: PANW) concerning potential breaches of fiduciary duties by certain directors of Palo Alto Networks, Inc.
Investors who are current long term investors in Palo Alto Networks, Inc. (NASDAQ: PANW) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current…
More Releases for Innate
Multiple Myeloma Diagnostic Market to Show Incredible Growth by 2027 | GlaxoSmit …
This Multiple Myeloma Diagnostic market research is based on anecdotal data, descriptive and inferential analysis by privacy advocates, and contributions from leading economists and collaborators throughout the manufacturing system. Because innovative technologies are grasped on a frequent basis in order to compete effectively and gain advantage over its rivals, our top sides and market experts have also been partnering hard to change the awareness of technological advances. As a result,…
Porcine Innate Immunity Market 2021 Clinical Analysis and Precise Outlook-NCBI, …
The “Porcine Innate Immunity Market” report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis.
The innate immune…
Natural Killer (NK) Cell Therapeutics Market 2021: Glycostem, Phio Pharmaceutica …
A new market study on the Natural Killer (NK) Cell Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. Natural Killer (NK) Cell Therapeutics Market helps to see what factors are influencing the business, where the brand is situated, and get the complete assessment of the market before a product is launched. the report elucidates complex details about…
Investigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: I …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Innate Pharma S.A.
Investors who are current long term investors in Innate Pharma S.A. (NASDAQ: IPHA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: IPHA stocks follows a lawsuit filed against Innate…
Lawsuit filed for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA)
An investor, who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA), filed a lawsuit over alleged violations of Federal Securities Laws by Innate Pharma S.A..
Investors who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) have certain options and for certain investors are short and strict deadlines running. Deadline: December 22, 2020. NASDAQ: IPHA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
France based Innate Pharma…
Walter Land: Crucial role of innate immune events in organ transplantation
"There is growing evidence that innate immune events provide critical initiating steps in immune responses to transplantation and key pathogenic steps in the tissue damage characteristic of humoral and cellular rejection. In fact, when I coined the term Innate Alloimmunity in 2002, I never foresaw the effect it would have on transplant thinking today," Professor Dr. Walter Land (Munich) emphasizes in his textbook "Innate Alloimmunity".
"This book reflects the beginning…
